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SHORT COMMUNICATION
Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients
with renal cell carcinoma correlate with response
A. Martens', R.A.J. Janssen', D.Th. Sleijfer2, A.A. Heijnl, N.H. Mulder2, T.H. The' &
L. de Leij'
Departments of'Clinical Immunology and 2Medical Oncology, University Hospital Groningen, The Netherlands.
Summary Plasma sIl-2R and sCD8 levels of 12 patients with renal cell carcinoma were determined before and
during subcutaneous rIl-2 therapy. Patients with a complete/partial remission showed a significantly stronger
initial increase of sCD8 compared to patients with stable disease or tumour progression.
Recombinant interleukin-2 (rIl-2) has induced clinical res-
ponses in patients with renal cell carcinoma and melanoma
(Philip et al., 1986; Rosenberg et al., 1987). rIl-2 is a glyco-
protein (MW = 15,000), normally generated by activated T-
(helper) cells and natural killer-(NK)-cells and which has
been shown to play an essential role in the activation,
differentiation and proliferation of T-cells, B-cells, monocytes
and NK-cells. I1-2 acts via membrane-bound receptors on
responding cells. The high affinity 11-2 receptor has a double
chain molecular structure; the p55 chain (CD25, I1-2-R-
alpha) and the p75 chain (Il-2-R-beta). The Il-2-R-beta alone
has an intermediate affinity for I1-2 and is operative in signal
transduction. In addition to membrane-bound II-2R the
existence of a soluble form of the interleukin-2 receptor has
been reported which is probably generated by proteolytic
cleavage of cell-surface bound p55. These soluble I1-2 recep-
tors (sIl-2R) are produced by activated, but not by resting, T
and NK cells (Farrar et al., 1982) and possibly also
monocytes (Kniep et al., 1992).
T suppressor/cytotoxic cells and a subpopulation of NK-
cells contain a membrane-bound CD8 molecule. CD8
stabilises MHC class I mediated cell-cell interactions, which
are involved in for instance MHC restricted T cell cytotox-
icity (Fleischer et al., 1986). During T cell activation CD8-
positive cells have been shown to release a soluble form of
the CD8 molecule (sCD8) (Tomkinson et al., 1989). This
± 30-kDa molecule originates as an alternative splicing prod-
uct of the CD8-precursor mRNA, in which the exon
encoding the transmembrane domain is deleted (Giblin et al.,
1989). The function and possible biological significance of
sCD8 is still unclear.
Soluble Il-2R and sCD8 serum concentrations have been
used as markers of T cell activation. During the proliferative
phase of the immune response in for example the first phase
of infection in measles high serum levels of sI12-R were
measured. During the effector phase of the induced immune
response (during the rash) the sCD8 serum concentration
reached a maximum (Griffin et al., 1989).
In the present study both sIl-2R and sCD8 levels were used
as parameters to study the changes in the immune system
during subcutaneously administered 11-2 in patients with
metastatic renal cell carcinoma.
Materials and methods
Patients
Of a group of 27 patients with histologically proven meta-
static renal-cell carcinoma who participated in a phase II
study of treatment with subcutaneous rIl-2 (Sleijfer et al.,
1992) twelve patients (four females, eight males; average age:
59 years, range 42-71) were included (at random for each
group: progressive disease, stable disease, partial/complete
remission) in this study. Two patients, because of neph-
rectomy were treated by chronic dialysis. No other diseases
apart from renal cancer were apparent and no patient was
under therapy with steroids. All patients were treated by
subcutaneously administered Cetus rIl-2 (EuroCetus, Amster-
dam, The Netherlands) 5 days per week followed by 2 days
of rest during 6 consecutive weeks. The first 5 days of the
first week 18 million I.U. were given and the first 2 days of
all further treatment weeks 9 million I.U. were given followed
by three days of 18 million units as described by Sleijfer et al.
(Sleijfer et al., 1990). Patients were grouped as follows:
patients 1-4 had progressive disease, patients 5-8 showed
stable disease and patients 9-12 had complete or partial
remission. A full report describing the clinical findings in
these patients have been published elsewhere (Sleijfer et al.,
1992).
Blood samples were obtained before and during treatment
three times a week. Within 1 h after obtaining the EDTA
blood sample (on ice) plasma was removed and frozen at
- 20°C until assayed.
Assays
The levels of soluble interleukin-2 receptor and soluble CD8
molecules were measured in plasma by sandwich enzyme
immunoassays with use of reagents and directions supplied
by the manufacturer (T Cell Sciences, Inc, Cambridge, Mas-
sachusetts). In short, both tests employ two noncompeting
monoclonal antibodies, one catching and one indicator
(horseradish peroxidase conjugated). Coated plastic micro-
wells were incubated with sample, washed and indicator
antibody was added. After washing the reaction mixture
(OPD) was added and the absorbance was measured.
The assays are calibrated on manufacturers' reference
preparations of culture supernatants. The intra-assay pre-
cision of the sIl-2R assay has a coefficient of variation
between 2-5%, the sCD8 assay between 4-8% (inter-assay
coefficient of variation: sIl-2R ± 5%, sCD8 ± 10%).
Both tests do not detect any known cross-reactive antigens
and no interference with haemoglobin, bilirubin, protein and
lipids have been shown. The detection limit for both tests is
± 50 U ml-'.
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Figure 1 Changes in sIl-2R concentration during therapy in a representative patient.
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Icoxon test, student t-test; see Appendix A).
e and peak values of sIl-2R and sCD8 concentration
during therapy
Ra sIl-2R' sCD8a sCD8b Ratio
se:
16896 340 511 1.50
12077 364 573 1.57
16487 415 833 2.01
24775 673 929 1.38
10923 428 899 2.10
17804 243 629 2.59
22268 660 1256 1.90
17879 400 940 2.35
18450 266 752 2.83
17170 422 1242 2.94
15062 265 725 2.74
17728 380 1405 3.70
17293 405 891
1416 14792-19795 313-496 703-1080
ntration before therapy. bPeak value during therapy.
,.95% c.i. = 95% confidence interval. Ratio: relative
sCD8 concentration.
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Figure 2 Changes in sCD8 concentration during therapy in a representative patient.
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Discussion
Although sera from the aged compared to young adults
contain higher levels of sIl-2R (65-82 years old: 604 ± 412 U
ml-') (Saadeh et al.,1986) patients with metastatic renal car-
cinoma prove to have relatively high base levels of soluble
11-2 receptor in the blood (mean RCC patients: 1074 ± 624 U
ml-', see Table I). Other studies (Lissoni et al., 1990) also
indicated increased sIl-2R concentration in patients with
solid tumours like breast cancer, small cell and non-small cell
lung cancer, colorectal cancer, gastric cancer and cervix car-
cinoma. It is unclear if these relatively high base levels reflect
an ongoing baseline activation of the immune system in these
patients. However, there seems no indication of an activation
of the effector phase of the immune response before therapy
as reflected by plasma sCD8 levels which were comparable to
(except the dialysis patients) the ones found in healthy per-
sons (138-533 U ml-').
During the subcutaneous administration of recombinant
interleukin-2 there was a strong rise of the sIl-2R plasma
concentration in all patients. In the first week of treatment
most patients did reach high levels (mean: 17.2 x baseline
level) of sI1-2R which remained high during the whole 6 week
treatment period (example: Figure 1). About the same in-
crease was seen in other studies (Lotze et al., 1987) where
interleukin-2 was administered i.v. (continuously as well as
intermittently). These results suggest that despite the
subcutaneous administration which did reduce toxicity
dramatically the immunological changes are as significant as
during the i.v. therapy.
Although the plasma sIl-2R concentration can be used as
an indicator of the proliferative phase of the immune res-
ponse a possible function of this soluble receptor molecule
remains obscure. It has been suggested that sI1-2R causes a
down-regulation of the immune response by for example
binding free 11-2 (Rubin et al., 1985). Other suggestions
however, that it may act as a chaperone for 11-2 seem to be
possible although the sIl-2R/II-2 complex has a molecular
weight of a mere 60-65 kD which is quite small for such a
function.
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During therapy we noted also an increase of the sCD8
plasma concentration. However, this rise was not as strongly
marked as the sII-2R increase and did not last during the
whole therapy cycle (see Figure 2). Most patients had a peak
concentration in the second week of treatment after which
the level returned to the baseline. Since the base sCD8 con-
centration varied between patients before treatment we cal-
culated the sCD8 ratio ([sCD8]peak value/[sCD8] before
therapy) so that each patient served as its own control.
Interestingly the patients with a partial or complete remission
showed a significantly higher relative increase of the sCD8
concentration in comparison with patients with stable or
progressive disease (Figure 3). These results indicate a cor-
relation between the relative sCD8 concentration increase
and the patients response rate.
High soluble CD8 levels appear to originate from interac-
tion of CD8 + effector cells with target cells (Fujimoto et al.,
1984). It is still not clear which cells during therapy are the
main source of the sCD8 production; the CD8 + T-cells or
the CD8 + NK-cells. The reason why sCD8 concentration
decreases again during the second half of therapy is unclear
since there seems to be a continued high status of activation
of the proliferative phase of the immune response as reflected
by the high plasma sI1-2R levels. These results may suggest
that during prolonged rIl-2 therapy (CD8 +) cytotoxic T
cells may become suppressed. So it may be possible that
continuing rIl-2 therapy after ± 3 weeks is less effective
because of the development of immune suppression.
In conclusion: during subcutaneous interleukin-2 therapy
of renal carcinoma there is a strongly marked activation of
the proliferative phase of the immune response reflected by
the strong plasma sIl-2R increasement. sCD8 is increased
only to a moderate extent. Importantly however, the sCD8
results show a correlation between the sCD8 plasma concen-
tration and the patients' response rate. During rIl-2 therapy a
form of immunosuppression involving CD8 + cells may
develop as is reflected by a lower sCD8 concentration in the
second half of therapy.
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Figure 3 Mean sCD8 ratio in the three patient groups; a = progressive disease, b = stable disease, c = remission.
Appendix A A small-sample test of a difference in means
Three patient groups: 1.
2.
3.
progressive disease
stable disease
remission
ratio [sCD8] peak value
[sCD8] before therapy
mean ratio group 1 = RI,
mean ratio group 2 = x2,
mean ratio group 3 = x3,
standard deviation = s,
standard deviation = S2
standard deviation = S3
RI = 1.615 s, =0.275 n, =4
(95% confidence interval: 1.178<jtI<2.05)
x2 = 2.235 s2 = 0.299 n2 = 4
(95% confidence interval: 1.760<j.2<2.710)
X3= 3.053 S3 = 0.439 n3 =4
(95% confidence interval: 2.355<A3<3.751)
Assuming - populations have a normal distribution
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Ho: A1-P2) = °
HI: JI:i+2
Test statistics:
95% confidence interval g2 - "1
(X2-RI) ± tl/2.s (1/nl + 1/n2)
where
(n, - 1)(SI)2 + (n2 - I)(s2)2
n, + n2 -2
rejection region: to.975 with (n1 + n2 - 2) degrees of freedom.
Calculation:
A. group 1 (progressive disease) and 2 (stable disease):
x2-x RI= 0.62
s = 0.287
to.975 (v = 6) = 2.45
0.123<A2-p, < 1.117:rejection Ho (2-10 = °)
B. group 2 (stable disease) and 3 (remission)
X3-X2 = 0.818
s = 0.376
t (v=6)=2.45
0.166<I3 -2< 1.469:rejection Ho (O3 - 12 = 0)
Conclusion: assuming a normal distribution of the ratios (of
[sCD8]) and roughly the same amount of variation in the
different patient groups there is a significant difference
(a = 0.05) between the means of the ratios of the three
different patient groups.
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